Cellectar Biosciences Reports Case Study Highlighting Complete Response Lasting More Than Eight Years in Heavily Pretreated DLBCL Patient Treated with Iopofosine I 131

James Caruso, President and Chief Executive Officer of Cellectar Biosciences

“This case study and results from iopofosine I 131 treatment of aggressive hematologic cancers along with the positive data generated to date in Waldenström macroglobulinemia further validate the PDC platform's ability to selectively target malignant cells.”

James Caruso, President and Chief Executive Officer of Cellectar Biosciences

“Importantly, we are now advancing our confirmatory Phase 3 study in WM and expect to initiate patient dosing in the first quarter of 2027, with plans remaining on target to submit an accelerated approval application to the U.S. Food and Drug Administration in the first half of 2027.”

Jarrod Longcor, Chief Operating Officer of Cellectar Biosciences

“While this case represents a single patient experience, we believe the durability and depth of response observed underscore the broader potential of iopofosine I 131 across B-cell malignancies.”

Jarrod Longcor, Chief Operating Officer of Cellectar Biosciences

“These findings reinforce the compelling clinical activity observed in our Phase 2b CLOVER WaM study, in which iopofosine I 131 delivered meaningful, durable responses in heavily pretreated patients with relapsed or refractory Waldenström macroglobulinemia, including those that were refractory to Bruton’s Tyrosine Kinase inhibitors.”